ArticleFrontiers in cellular and infection microbiology2020
Unraveling
Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Design, Synthesis, and Antibiofilm Efficacy of Ag/Se-Doped CuO-Chitosan Nanocomposites as Potent Antifungal Agents Against Candida albicans.Chemistry & biodiversity · 2026Article
- Chemical profile, anti-biofilm and antioxidant activities of Cymbopogon citratus (DC.) Stapf essential oil.BMC complementary medicine and therapies · 2026Article
- Co-variation between blood stream infections with Candida species versus Pseudomonas aeruginosa, Staphylococcus aureus, and other isolates among 60 ICU patient cohorts.Medical mycology · 2026Article
- Outbreak ofFrontiers in microbiology · 2026Article
- A comprehensive analysis of the effect of quorum-sensing molecule 3-oxo-C12-homoserine lactone onBiofilm · 2025Article
- Associations Between Candida andMicroorganisms · 2025Article
- Exploring the bioactive landscape: peptides and non-peptides from the human microbiota.NPJ biofilms and microbiomes · 2025Review
- Evaluation of the antagonistic effect ofIranian journal of microbiology · 2025Article
- Harnessing Cyclic di-GMP Signaling: A Strategic Approach to Combat Bacterial Biofilm-Associated Chronic Infections.Current microbiology · 2025Review
- Who arrived first? Priority effects on Candida albicans and Pseudomonas aeruginosa dual biofilms.Communications biology · 2025Article
- Antagonistic effect ofFrontiers in fungal biology · 2025Article
- Long-chain 4-aminoquinolines inhibit filamentation and increase efficacy of nystatin against Candida albicans infections in vivo.NPJ biofilms and microbiomes · 2024Article
- Deciphering microbiome and fungi-bacteria interactions in chronic wound infections using metagenomic sequencing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Structural Equation Modelling as a Proof-of-Concept Tool for Mediation Mechanisms Between Topical Antibiotic Prophylaxis and Six Types of Blood Stream Infection Among ICU Patients.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.Archives of microbiology · 2024Review
- A gain-of-function mutation in zinc cluster transcription factor Rob1 drives Candida albicans adaptive growth in the cystic fibrosis lung environment.PLoS pathogens · 2024Article
- Candida-bacterial cross-kingdom interactions.Trends in microbiology · 2023Review
- Surface adherence and vacuolar internalization of bacterial pathogens to the Candida spp. cells: Mechanism of persistence and propagation.Journal of advanced research · 2023Review
- Revealing the Bacterial Quorum-Sensing Effect on the Biofilm Formation of DiatomMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern medicine is currently facing huge setbacks concerning infection therapeutics as microorganisms are consistently knocking down every antimicrobial wall set before them. The situation becomes more worrying when taking into account that, in both environmental and disease scenarios, microorganisms present themselves as biofilm communities that are often polymicrobial. This comprises a competitive advantage, with interactions between different species altering host responses, antimicrobial effectiveness, microbial pathogenesis and virulence, usually augmenting the severity of the infection and contributing for the recalcitrance towards conventional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.